ライフサイエンスコーパス: cytochrome P450

1 hly active synthetic models of compound I of cytochrome P450.

2 nd closure via the upregulation of mtROS and Cytochrome P450.

3 X2 and an increase LMs products of ALOX5 and cytochrome p450.

4 lished enzymes leading to oxidations such as cytochrome P450.

5 bacterial LPS, alter the expression of many cytochromes P450.

6 hus potentially decreasing the dependence on cytochromes P450.

7 Human cytochrome P450 11B1 (CYP11B1) is responsible for the fi

8 Aldosterone synthase (AS, cytochrome P450 11B2, cyp11B2) is the sole enzyme respon

9 The clinical utility of inhibiting cytochrome P450 17A1 (CYP17), a cytochrome p450 enzyme t

10 1C2], aldo-keto reductase type 1C4 [AKR1C4], cytochrome P450 17A1 [CYP17A1]), as measured by quantita

11 roidogenic factor, steroid acute regulatory, cytochrome-P450-17A1, dosage-sensitive, sex-reversal, ad

12 describes the linkage between inhibition of cytochrome P450 19A aromatase (the MIE) and population-l

13 Aromatase, or cytochrome P450 19A1, catalyzes the aromatization of and

14 there was an increase in gene expression of cytochrome P450 1A but not glutathione S-transferase.

15 The androgen receptor (ar) and cytochrome P450 1A genes were associated with large shif

16 The 3-methylcholanthrene responsive cytochrome P450-1a ( cyp1a) transcript exhibited the gre

17 The liver enzyme cytochrome P450 1A2 (CYP1A2) is responsible for 90% of c

18 ndividuals who carry a functional variant at cytochrome P450 1A2 (CYP1A2), which makes them less effe

19 atively by LiMAx test (enzymatic capacity of cytochrome P450 1A2).

20 The mammalian ancestor of the cytochrome P450 1B subfamily was herein characterized st

21 synthesizing and -degrading enzymes, such as cytochrome P450 26 (Cyp26 genes).

22 /central zones during embryogenesis requires Cytochrome P450 26b1 (Cyp26b1)-mediated degradation of r

23 Cytochrome P450 27A1 (CYP27A1 or sterol 27-hydroxylase)

24 Cytochrome P450 27A1 (CYP27A1) is a ubiquitous enzyme th

25 d because of their higher prevalence of poor cytochrome P450 2C19 metabolizers.

26 mg/day (36 mg/day for patients taking strong cytochrome P450 2D6 (CYP2D6) inhibitors).

27 Cytochrome P450 2D6 (CYP2D6) is a highly polymorphic gen

28 Evidence suggests that the hepatic isoenzyme cytochrome P450 2D6 (CYP2D6) is the key enzyme required

29 eviously that mitochondrially targeted human cytochrome P450 2D6 (CYP2D6), supported by mitochondrial

30 knockout (KO) mice have increased levels of cytochrome P450 2E1 (CYP2E1), but the underlying mechani

31 show that a detoxifying transgene, mammalian cytochrome P450 2e1 can be expressed in a houseplant, Ep

32 Cytochrome P450 2J2 (CYP2J2) is responsible for the epox

33 Cytochrome P450 3A is the most important CYP subfamily i

34 oral administration, only mild inhibition of cytochrome P450 3A, and no evidence of cardiac- or photo

35 unds was also tested for metabolism by human cytochrome P450 3A4 (CYP3A4) and human aldehyde oxidase

36 Human cytochrome P450 3A4 (CYP3A4) is a major hepatic and inte

37 Inhibition of cytochrome P450 3A4 (CYP3A4), the major drug metabolizin

38 X receptor helped in overcoming a persistent cytochrome P450 3A4 induction problem.

39 Cytochrome P450 3A4 isoform (CYP3A4) transcription is co

40 de novo donor-specific antibody development, cytochrome P450 3A5 genotype, pregraft sensitization, mo

41 model, based on 666 patients with available cytochrome P450 3A5 genotypes, the effect of the C/D rat

42 Efavirenz (EFV) is an anti-HIV drug, and cytochrome P450 46A1 (CYP46A1) is the major brain choles

43 Cytochrome P450 46A1 (CYP46A1) or cholesterol-24-hydroxy

44 Cytochrome P450 46A1 (CYP46A1, cholesterol 24-hydroxylas

45 (PPARalpha), which induces transcription of cytochrome P450 4A (CYP4A).

46 oxicity against cancer cell lines expressing cytochrome P450 4F11.

47 Mammary-tissue-restricted cytochrome P450 4Z1 (CYP4Z1) has garnered interest for i

48 By the time cytochrome P450 7A1 expression is reduced these drugs ma

49 or hepatocellular bile salt transporters and cytochrome P450 7a1, the key regulator of bile salt synt

50 ABCG8], sulfotransferase family 2A member 1, cytochrome P450 7A1, transmembrane 4 L six family member

51 The key BA synthesis enzyme cytochrome P450 A1 was absent in MGC and CGC; BA product

52 rformance (i.e. urea and albumin production, cytochrome P450 activity and induction studies) of the p

53 compared with static organoid cultures, and cytochrome p450 activity reached levels equivalent to he

54 explained by the effect of the two azoles on cytochrome P450 activity, measured on D. magna in vivo.

55 inal chemists to stabilize candidates toward cytochrome P450 activity, which increases the risk for n

56 eas imidazole directly kills Mtb by reducing cytochrome P450 activity.

57 ecretion of albumin and apolipoprotein B and cytochrome P450 activity; cholangiocytes were functional

58 Surprisingly, this cytochrome P450 also catalyzes the non-oxidative isomeri

59 synthesis, which involves a uniquely adapted cytochrome P450-amidotransferase enzyme pair and highlig

60 pathway was expressed including a different cytochrome P450, an alcohol oxidase and an alcohol dehyd

61 ivatives including AlkB and AlmA, two CYP153 cytochrome P450s, an alcohol dehydrogenase and an aldehy

62 zid (INH) and rifampicin (RIF), which affect cytochrome P450 and antiretroviral exposure.

63 achio is likely attributable to the expanded cytochrome P450 and chitinase gene families.

64 to the heme proteins hemoglobin, myoglobin, cytochrome P450 and cytochrome c, respectively.

65 3 is a natural fusion protein constructed of cytochrome P450 and NADPH-cytochrome P450 reductase doma

66 Given that DHA metabolism by cytochrome P450 and soluble epoxide hydrolase (sEH) enzy

67 Here, we report the discovery of five cytochrome P450s and two acetyltransferases which cataly

68 hydroxylase, thiolate-ligated heme-dependent cytochrome P450, and four nonheme oxygenases, namely, te

69 for 3 technically important enzymes (PETase, cytochrome P450, and organophosphorus hydrolase).

70 s ago to help explain reactivity patterns in cytochrome P450, and subsequently has been used to provi

71 The cytochromes P450 are heme-dependent enzymes that catalyz

72 CYPs (cytochrome p450) are critically involved in the metaboli

73 Here we provide evidence that cytochrome P450 aromatase (AROM), the enzyme converting

74 which reportedly regulates the expression of cytochrome P450 aromatase (P450arom).

75 in mood disorders and of the side effects of cytochrome P450 aromatase inhibitors, which are frequent

76 the significant potential and plasticity of cytochrome P450 aromatic O-demethylases in the biologica

77 Using this approach, a cytochrome P450(BM3) mutant library was successfully scr

78 e first to be characterized as an inducer of cytochrome P450 by activation of the constitutive andros

79 It has become increasingly clear that cytochromes P450 can cycle back and forth between two ex

80 ubstrate addition is one of the key steps in cytochrome P450 catalysis.

81 te thermodynamics for C-H bond activation in cytochrome P450 catalysis.

82 er reports the discovery of highly selective cytochrome P450-catalyzed methylcubane oxidations which

83 Biosynthetic pathways involving cytochrome P450-catalyzed oxidation of fatty acids in ye

84 ction, we have prepared a selenolate-ligated cytochrome P450 compound I intermediate.

85 Prodrug-mediated utilization of the cytochrome P450 (CYP) 1A1 to obtain the selective releas

86 earance of atRA is primarily mediated by the cytochrome P450 (CYP) 26 enzymes, which play an essentia

87 Previous studies implicate cytochrome P450 (CYP) 2B11 as an important clearance mec

88 in vitro assessment confirmed inhibition of cytochrome P450 (CYP) 2C19 and CYP3A4 by meropenem, sugg

89 We identified rifamycin induced DMEs, cytochrome P450 (CYP) 2C8/3A4/3A5, SULT2A, and UGT1A4/1A

90 Expressed in the vascular endothelium, cytochrome P450 (CYP) 2J2 is one of the CYP epoxygenases

91 Both fasting and diabetes suppressed hepatic cytochrome P450 (CYP) 2R1, the main vitamin D 25-hydroxy

92 Cytochrome P450 (CYP) 3A accounts for nearly 30% of the

93 Cytochrome P450 (CYP) 3A4 is a major contributor to hepa

94 chlorinated biphenyls (PCBs) is initiated by cytochrome P450 (CYP) enzymes and includes PCB oxidation

95 Toxicokinetic interactions with catabolic cytochrome P450 (CYP) enzymes can inhibit chemical elimi

96 The human cytochrome P450 (CYP) enzymes CYP3A4 and CYP3A5 metaboli

97 Arachidonic acid epoxides generated by cytochrome P450 (CYP) enzymes have been linked to increa

98 on, the functional role of drug metabolizing cytochrome P450 (CYP) enzymes in human plasma exosomes a

99 The superfamily of hepatic cytochrome P450 (CYP) enzymes is responsible for the int

100 Human cytochrome P450 (CYP) enzymes play an important role in

101 om the crosstalk between endocannabinoid and cytochrome P450 (CYP) epoxygenase metabolic pathways.

102 Cytochrome P450 (CYP) family members are known to be pre

103 polyunsaturated fatty acids derived from the cytochrome P450 (CYP) monooxygenase pathway serve as vit

104 examine the role of Phase I and II enzymes (cytochrome P450 (CYP), uridine glucuronic acid transfera

105 ypothesized to be derived from discoidol via cytochrome P450 (CYP)-catalyzed oxidative cleavage.

106 cyclooxygenase (COX), lipoxygenase (LOX), or cytochrome P450 (CYP).

107 Cytochrome P450 (CYP)1A enzymes are protective against h

108 Cytochrome P450 (CYP)3A is the most abundant CYP enzyme

109 Genes encoding cytochrome P450 (CYP; P450) enzymes occur widely in the

110 nzymes responsible for drug metabolism (i.e. cytochrome P450 [CYP] 3A4, CYP1A2).

111 The bacterial cytochrome P450 CYP101B1 from Novosphingobium aromaticiv

112 Multiple cytochrome P450 (CYP1A1, CYP2A19 and CYP2C36) genes disp

113 Although the cytochrome P450 CYP27B1 plays a critical role in vitamin

114 bumin (ALB) expression and also analyzed for cytochrome P450 (CYP3A4) zonation and glycogen accumulat

115 d pheromones in the MG, including members of cytochrome P450 (CYP450) family and genes involved in fa

116 Intracellular enzymes, such as cytochrome P450 (CYP450), have also been suggested to co

117 ere we report on a terpene synthase (DdTPS8)-cytochrome P450 (CYP521A1) gene cluster that produces a

118 cient in flavodiiron proteins (FLVs) or in a cytochrome p450 (CYP55), we show that FLVs contribute to

119 a candidate gene encoding an uncharacterized cytochrome P450, CYP71A27 Loss of this gene resulted in

120 conversion to leubethanol is catalyzed by a cytochrome P450 (CYP71D616) of the CYP71 clan.

121 This leads to the identification of a cytochrome P450 (CYP728B70) that can catalyze oxidation

122 maize PLASTOCHRON1 (ZmPLA1) gene, encoding a cytochrome P450 (CYP78A1), results in increased organ gr

123 luated whether tyrosine hydroxylase (TH) and cytochrome P450s (CYPs) catalyzed this process.

124 Cytochromes P450 (CYPs) catalyze various oxidative trans

125 ple organs and selected supersomes of single cytochrome P450 (cyt P450) enzymes on the magnetic beads

126 interactions of full-length mammalian 72-kDa cytochrome P450-cytochrome b5 complex in lipid bilayers.

127 membrane protein vital for the regulation of cytochrome P450 (cytP450) metabolism and is capable of e

128 Epoxy-fatty-acids (EpFAs), cytochrome P450 dependent arachidonic acid derivatives,

129 Cytochrome P450-dependent metabolism of the anti-HIV dru

130 Cytochrome-P450-derived anti-inflammatory and cardioprot

131 The role of cytochrome P450 drug metabolizing enzymes in the efficac

132 been proposed that such chemoresistance via cytochrome P450/drug transporters can be reversed with t

133 ls suggest that changes in the production of cytochrome P450 eicosanoids alter BP.

134 review summarizes the emerging evidence that cytochrome P450 eicosanoids have a role in the pathogene

135 raenoic acid (20-HETE), one of the principle cytochrome P450 eicosanoids, is a potent vasoactive lipi

136 arvae relative to adults may be due to lower cytochrome P450 enzyme activity in fat bodies.

137 We identified a cytochrome P450 enzyme AsCYP72A475 as a triterpene C-21b

138 Here, we report the characterization of the cytochrome P450 enzyme BotCYP from a bottromycin biosynt

139 Here we report the engineering of a cytochrome P450 enzyme by directed evolution to catalyze

140 Screening of a 48-variant library of the cytochrome P450 enzyme CYP102A1 (P450BM3), followed by t

141 (1,25(OH)2D3), occurs in the kidney via the cytochrome P450 enzyme CYP27B1.

142 CYP121, the cytochrome P450 enzyme in Mycobacterium tuberculosis tha

143 The catalysts, derived from a cytochrome P450 enzyme in which the native cysteine axia

144 CYP3A4, a cytochrome P450 enzyme regulated by the nuclear receptor

145 Sterol 14alpha-demethylase (CYP51) is a cytochrome P450 enzyme required for biosynthesis of ster

146 CYP46A1 is the cytochrome P450 enzyme that converts cholesterol to 24-h

147 characterization of vinorine hydroxylase, a cytochrome P450 enzyme that hydroxylates vinorine to for

148 f inhibiting cytochrome P450 17A1 (CYP17), a cytochrome p450 enzyme that is required for the producti

149 CYP17A1 is a cytochrome P450 enzyme with 17-alpha-hydroxylase and C17

150 ithelium (RPE), TH regulates expression of a cytochrome P450 enzyme, cyp27c1, that converts vitamin A

151 oxyresorufin-O-deethylase (EROD) activity of cytochrome P450 enzymes and continuous accumulation of f

152 = 8.5, pEC(50) = 9.5) with weak activity on cytochrome P450 enzymes and good metabolic stability.

153 ay for the metabolism of arachidonic acid by cytochrome P450 enzymes emerged.

154 We further identify coexpressed cytochrome P450 enzymes from M. azedarach (MaCYP71CD2 an

155 Cytochrome P450 enzymes have been engineered to catalyze

156 Cytochrome P450 enzymes have tremendous potential as ind

157 Mammalian cytochrome P450 enzymes often metabolize many pharmaceut

158 ol (THC), are metabolized and inactivated by cytochrome P450 enzymes primarily within the liver.

159 Sterol 14alpha-demethylases (CYP51) are the cytochrome P450 enzymes required for biosynthesis of ste

160 Reconstructed ancestral cytochrome P450 enzymes tend to have variable substrate

161 oat transcriptome data to identify candidate cytochrome P450 enzymes that may catalyse C-21beta oxida

162 In this study, we report engineered cytochrome P450 enzymes that perform unprecedented enant

163 report a biocatalytic platform of engineered cytochrome P450 enzymes to carry out efficient cycloprop

164 Using directed evolution, we engineered cytochrome P450 enzymes to catalyze this abiological rea

165 in biosynthesis, including ABC transporters, cytochrome P450 enzymes, and an acyltransferase.

166 ivity of drugs across multiple steroidogenic cytochrome P450 enzymes, provide a structural basis for

167 ree kratom alkaloids tested inhibited select cytochrome P450 enzymes, suggesting a potential risk for

168 se (CPR) is the redox partner for most human cytochrome P450 enzymes.

169 xidative aromatic cross-linking performed by cytochrome P450 enzymes.

170 ment with 4-phenylimidazole, an inhibitor of cytochrome P450 enzymes.

171 thiolate-heme containing epoxidases, such as cytochrome P450 epoxidases.

172 lly expressed genes, chitinase 1 (CHIT1) and cytochrome P450 family 1 subfamily B member 1 (CYP1B1),

173 Cytochrome P450 family 102 subfamily A member 1 (CYP102A

174 The human cytochrome P450 family 11 subfamily B member 2 (hCYP11B2

175 e polymorphism (SNP) rs7175922 in aromatase (cytochrome P450 family 19 subfamily A member 1 [CYP19A1]

176 ify novel phenotypic associations related to Cytochrome P450 Family 2 Subfamily A Member 6 (CYP2A6),

177 e previously reported that overexpression of cytochrome P450 family 24 subfamily A member 1 (CYP24A1)

178 D responsive genes, 25(OH)D3-24-hydroxylase (cytochrome P450 family 24 subfamily A member 1) mRNA exp

179 om responding to RA by catabolic activity of cytochrome P450 family 26 enzymes.

180 ediated increases in homeobox A1 (Hoxa1) and cytochrome P450 family 26 subfamily A member 1 (Cyp26a1)

181 Cytochrome P450 family 26 subfamily B member 1 (CYP26B1)

182 Cytochrome P450 family 27 subfamily B member 1 (CYP27B1)

183 -dihydroxyvitamin D(3) (1,25(OH)(2)D(3)) via cytochrome P450 family 27 subfamily B member 1 (CYP27B1)

184 ry low level of 25(OH)D3-1alpha-hydroxylase (cytochrome P450 family 27 subfamily B member 1), and the

185 -3-methylglutaryl-CoA reductase (Hmgcr), and cytochrome P450 family 7 subfamily A member 1 (Cyp7a1),

186 y expressed, flower-specific gene encoding a cytochrome P450 family 79D protein (PrCYP79D73), which c

187 A further T cinerariifolium cytochrome P450 family member, CYP82Q3 (designated Pyret

188 CYP2J2, a member of the Cytochrome P450 family of enzymes, is the most abundant

189 whereas all genes coding for members of the cytochrome P450 family were upregulated.

190 Common genetic variation in CYP2C19 (cytochrome P450, family 2, subfamily C, polypeptide 19)

191 process is dependent on hepatic induction of cytochrome P450, family 7, subfamily b, polypeptide 1 (C

192 We addressed this challenge by evolving a cytochrome P450 for highly efficient carbene transfer to

193 ed structure with those of well-investigated cytochromes P450 from mammals and bacteria enabled us to

194 We studied a cytochrome P450 gene from A. officinalis, AoCYP94B1, and

195 we show that cis-regulatory variants of the cytochrome P450 gene, CYP6P9b, are associated with pyret

196 iption analysis identified overexpression of cytochrome P450 genes as the main mechanism driving this

197 h a massive overexpression of the duplicated cytochrome P450 genes CYP6P9a and CYP6P9b, and also the

198 A number of cytochrome P450 genes were downregulated in response to

199 rbicide metabolism-based resistances include cytochromes P450, GSH S-transferases, glucosyl and other

200 n-donation from the axial thiolate ligand of cytochrome P450 has been proposed to increase the reacti

201 Cytochromes P450 have been recently identified as a prom

202 usion enzyme comprising two major domains: a cytochrome P450 (heme-binding) catalytic domain and a NA

203 activities of a BAHD acyltransferase and two cytochrome P450 hydroxylases.

204 f medically and biocatalytically significant cytochrome P450s in cell lysate, microsomes, and bacteri

205 cterium tuberculosis H37Rv genome encodes 20 cytochromes P450, including P450s crucial to infection a

206 , improving metabolic stability and reducing cytochrome P450 inhibition driven drug-drug interaction

207 ased selectivity against PR and AR, improved cytochrome P450 inhibition profile, and significantly im

208 ed Nrf2-luc response were ameliorated by the cytochrome P450 inhibitor aminobenzotriazole.

209 tastatic suppressor KAI1 but also of hepatic cytochromes P450, is upregulated in various human cancer

210 an isoform-specific probe for CYP3A4, a key cytochrome P450 isoform responsible for the oxidation of

211 ther taxa, NMP is primarily detoxified via a cytochrome P450 mediated pathway.

212 tical review of the evidence for presence of cytochrome P450-mediated metabolic resistance mechanisms

213 of in vivo glycosylation, selective in vitro cytochrome P450-mediated oxidation, and chemical oxidati

214 ntial for drug interactions due to competing cytochrome P450 metabolism between statins and commonly

215 (19,20-EDP), a naturally occurring bioactive cytochrome P450 metabolite of docosahexaenoic acid, a ma

216 ,18(S)-Epoxyeicosatetraenoic acid (EEQ) is a cytochrome P450 metabolite of eicosapentaenoic acid (EPA

217 Using a LC-MS method, putative cytochrome P450 metabolites of NMP were identified and q

218 orest (AUC = 0.83 [0.69, 0.96]), followed by cytochrome p450 metabolites using adaptive elastic-net (

219 Here the first example of a wild-type cytochrome P450 monooxygenase (CYP116B46 from Tepidiphil

220 Additionally, a cytochrome P450 monooxygenase (CYP99A17), which genomica

221 We report that a wild-type cytochrome P450 monooxygenase (P450(BM3) from Bacillus m

222 Cinnamate 4-hydroxylase (C4H; CYP73A) is a cytochrome P450 monooxygenase associated externally with

223 The cytochrome P450 monooxygenase P450 BM3 (BM3) is a biotec

224 Cytochrome P450 monooxygenase was involved in the produc

225 the most rapid hole hopping escape routes in cytochrome P450 monooxygenase, cytochrome c peroxidase,

226 They are synthesized by cytochrome P450 monooxygenases (CYPs) and degraded by so

227 own inhibitors of the important enzyme class cytochrome P450 monooxygenases (CYPs), thereby influenci

228 Cytochrome P450 monooxygenases (CYPs/P450s), heme thiola

229 Cytochrome P450 monooxygenases (P450) in the honey bee,

230 Cytochrome P450 monooxygenases (P450s) found in all doma

231 Cytochrome P450 monooxygenases (termed CYPs or P450s) ar

232 extremely large repertoire of genes encoding cytochrome P450 monooxygenases and glutathione S-transfe

233 erentially expressed genes (DEGs), including cytochrome P450 monooxygenases and UDP-glycosyltransfera

234 Cytochrome P450 monooxygenases CYP101A1 and MycG catalyz

235 Direct epoxidation of aromatic nuclei by cytochrome P450 monooxygenases is one of the major metab

236 Cytochrome P450 monooxygenases play a critical role in i

237 ion of genes encoding diterpenoid synthases, cytochrome P450 monooxygenases, 2-oxoglutarate-dependent

238 is enhanced ca.1000 fold in the presence of cytochrome P450 NADPH:oxidoreductase (CPR) from the live

239 Genome mining enabled identification of the cytochrome P450, NzeB (Streptomyces sp. NRRL F-5053), wh

240 he omega-3 and the omega-6 lipid products of cytochrome P450 oxidase 2C promote neovascularization in

241 We also found that cytochrome P450 oxidases involved in cutin and suberin p

242 otic detoxification programme and identified cytochrome P450 oxidases, the KLF-1 main effectors, as l

243 0.05) following oral THC administration for cytochrome P450 oxidoreductase (Por), involved in toxin

244 TcJMH belongs to the CYP71 clade of the cytochrome P450 oxidoreductase family.

245 on of canonical bioreductive enzymes such as cytochrome P450 oxidoreductase is likely to be futile.

246 enzyme reduction by the redox partner NADPH-cytochrome P450 oxidoreductase, and the amount of P450 r

247 n 10 (C10) to a carboxylic group by TcCHH, a cytochrome P450 oxidoreductase.

248 Human cytochrome P450 (P450) 11B2 catalyzes the formation of a

249 Cytochrome P450 (P450) 17A1 catalyzes the oxidations of

250 Both enantiomers of this inhibitor of cytochrome P450 (P450) 17A1 show some selectivity in dif

251 Recently, zebrafish and human cytochrome P450 (P450) 27C1 enzymes have been shown to b

252 Cytochrome P450 (P450) 3A4 is the enzyme most involved i

253 Human cytochrome P450 (P450) CYP2B6 undergoes nitric oxide (NO

254 tin-dependent proteasomal degradation of the cytochrome P450 (P450) enzyme CYP2B6.

255 Cytochrome P450 (P450) enzymes are major catalysts invol

256 ; however, the formation of OH-PCBs by human cytochrome P450 (P450) isoforms is poorly investigated.

257 ere JBC's extensive coverage of the field of cytochrome P450 (P450) research.

258 Cytochrome P450 (P450, CYP) 17A1 plays a critical role i

259 Cytochrome P450 (P450, CYP) 21A2 is the major steroid 21

260 Cytochrome P450 (P450, CYP) enzymes are the major cataly

261 Cytochromes P450 (P450, CYP) metabolize a wide variety o

262 Heme oxygenase 1 (HO-1) and the cytochromes P450 (P450s) are endoplasmic reticulum-bound

263 Cytochromes P450 (P450s) are nature's catalysts of choic

264 reticulum (ER)-anchored monotopic proteins, cytochromes P450 (P450s), are enzymes that metabolize en

265 ereas anti-inflammatory metabolites from the cytochrome P450 pathway were reduced in cART/HIV-1-expos

266 Many family 4 cytochrome P450s play key roles in fatty acid hydroxylat

267 of the mice treated with OCA, the levels of cytochrome P450 potentially involved in VPA metabolism w

268 ct metabolism-an alcohol dehydrogenase and a cytochrome P450-produces unexpected rearrangements in st

269 Among eicosanoids, lipoxygenase and cytochrome p450 products performed best in identifying o

270 selectivity versus other PDE enzymes, clean cytochrome P450 profile, in vivo target occupancy, and p

271 The cytochrome P450 proteins contain heme as a cofactor and

272 It lacks all genes encoding heme-containing cytochrome P450 proteins.

273 (heme-binding) catalytic domain and a NADPH-cytochrome P450 reductase (CPR) domain containing FAD an

274 nd CYP6AA7 were separately co-expressed with cytochrome P450 reductase (CPR) in insect Spodoptera fru

275 Cytochrome P450 reductase (CPR) is the redox partner for

276 me b5 (B5)/cytochrome b5 reductase (B5R) and cytochrome P450 reductase (CPR) were measured in aortic

277 enzymes that rely on the same protein, NADPH-cytochrome P450 reductase (POR), to provide the electron

278 nctioned as type I nitroreductase (TbNTR) or cytochrome P450 reductase (TbCPR) dependent prodrugs tha

279 The enzyme uses NADPH-cytochrome P450 reductase as a donor of electrons and hy

280 ein constructed of cytochrome P450 and NADPH-cytochrome P450 reductase domains.

281 NADPH-cytochrome P450 reductase is a multi-domain redox enzyme

282 nes encoding known redox partners for P450s (cytochrome P450 reductase, ferredoxin and ferredoxin red

283 Cytochrome P450-reductase (CPR) is a versatile NADPH-dep

284 ural evaluation of a reconstructed ancestral cytochrome P450, revealing key features that appear to c

285 gene expansions in the glycosyltransferase, cytochrome P450, shikimate hydroxycinnamoyl transferase,

286 Cytochrome P450 side-chain cleavage enzyme (SCC or CYP11

287 d alpha-linolenic acid, respectively) in the cytochrome P450/soluble epoxide hydrolase pathway.

288 For the past 40 years, my interest has been cytochrome P450 structure-function and structure-activit

289 production improves subsequent decoration by cytochrome P450s, supporting efficient conversion of (S)

290 Recently, a cytochrome P450 system, GcoAB, was discovered to demethy

291 nhibit warfarin deactivation via the hepatic cytochrome P450 system.

292 apsigargin biosynthesis, by showing that the cytochrome P450 TgCYP76AE2, transiently expressed in Nic

293 edness with F3'Hs in the CYP75B subfamily of cytochromes P450 than with those with known F3'5'H activ

294 Notably, we identified a non-canonical cytochrome P450 that catalyses the remarkable ring expan

295 eds led to the identification of CYP88A13, a cytochrome P450 that catalyzes the C-16alpha hydroxylati

296 le of CYP46A1, an important brain enzyme and cytochrome P450 that could be activated pharmacologicall

297 re we report enzyme catalysts derived from a cytochrome P450 that use a nitrene transfer mechanism fo

298 51 enzymes (sterol 14alpha-demethylases) are cytochromes P450 that catalyze multistep reactions.

299 plants have independently recruited pairs of cytochromes P450 that catalyze oxidative 5,6-spiroketali

300 ) is metabolized by cyclooxygenase (COX) and cytochrome P450 to produce proangiogenic metabolites.